Document:

<PAGE>
                                                                   Exhibit 10.13

                                                                  EXECUTION COPY

                             SHAREHOLDERS AGREEMENT

         This Shareholders Agreement (the "Agreement") is made as of August 1,
2001, by and among W.R. Hambrecht/QIC, LLC, a California limited liability
company ("WRH/QIC"), Philips Electronics North America Corporation, a Delaware
corporation ("PENAC") (collectively, the "Shareholders"), and W.R. Hambrecht/QIC
Management, LLC, a California limited liability company (the "Manager"), and
such other persons who execute this Agreement from time to time and thereby
agree to be bound by this Agreement as Shareholders.

                                    RECITALS

A.       Each of the Shareholders is now or may become the owner of shares of
voting stock of QIC Holding Corp., a California corporation, or any successor
(the "Holding Company").

B.       As a material inducement to the purchase by WRH/QIC and Hewlett-Packard
Company, a Delaware corporation ("HP"), of their respective shares in the
Holding Company, WRH/QIC, HP and the Manager entered into a Shareholders
Agreement, dated as of May 27, 1998 (the "Original Shareholders Agreement"),
with respect to the voting and transfer of the shares in the Holding Company
held by WRH/QIC and HP, including any other shares of the Holding Company's
capital stock which might thereafter be owned by WRH/QIC and HP (the "Shares"),
for the purpose of protecting WRH/QIC and HP, as well as providing continuity
for the Holding Company's business in the event of the occurrence of certain
events discussed in the Original Shareholders Agreement.

C.       WRH/QIC is organized under the terms of an Operating Agreement dated as
of April 22, 1998 (the "Operating Agreement"). As a material inducement to the
purchase by HP of its shares in the Holding Company, the members of WRH/QIC
agreed pursuant to the terms of the Operating Agreement to restrict their
ability to transfer their interests in WRH/QIC in any manner which would be
inconsistent with or in violation of the terms of the Original Shareholder
Agreement and the Manager agreed to enforce such restrictions.

D.       On August 12, 1999, HP and Agilent Technologies, Inc., at that time a
wholly-owned subsidiary of HP ("Agilent"), entered into a Master Separation and
Distribution Agreement under which HP transferred to Agilent, pursuant to
Section 2.6 of the Original Shareholders Agreement, its shares in the Holding
Company.

E.       On November 17, 2000, Agilent and Koninklijke Philips Electronics N.V.
("KPNV"), entered into an Asset Purchase Agreement which, among other things,
provided for the transfer by Agilent to KPNV or one of its affiliates of
Agilent's shares in the Holding Company. In accordance with Section 2.3 of the
Original Shareholders Agreement, Agilent provided WRH/QIC with a First Refusal
Notice of the anticipated transfer and WRH/QIC declined to exercise the right of
first refusal related thereto.

F.       PENAC is an indirect, wholly-owned subsidiary of KPNV.

G.       To complete the transfer of shares from Agilent to PENAC in accordance
with Section 7 of the Original Shareholder Agreement, WRH/QIC and PENAC now
desire to enter into this Shareholders Agreement.

                  NOW, THEREFORE, the Shareholders agree as follows:

1.       COMPOSITION OF BOARD OF DIRECTORS. The Board of Directors of the
Holding Company shall consist of five (5) members. Each of the Shareholders
shall vote all of its shares now or hereafter owned by it so that each of the
following is elected as a director of the Holding Company: (i) three (3)
nominees of WRH/QIC; (ii) one (1) nominee of PENAC; and (iii) one (1) nominee of
Zymed, Incorporated ("Zymed"). Prior to each election of directors of the
Holding Company, WRH/QIC, PENAC, and Zymed shall designate their respective
nominees in writing to the Holding Company. The Holding Company shall promptly
notify the Shareholders of these nominees.

         1.1 NUMBER OF DIRECTORS. The Shareholders agree that they will not vote
to increase the number of directors of the Holding Company beyond seven (7), nor
below five (5), without the consent of PENAC, which shall not be unreasonably
withheld.
<PAGE>
2.       RESTRICTION ON CERTAIN TRANSFERS OF CONTROL. Except as provided in this
Agreement, no Shareholder shall voluntarily sell, assign, transfer, give,
bequeath, donate or otherwise dispose of, or pledge, deposit, or otherwise
encumber, in any manner, any of the Shares.

         2.1 PENAC'S RIGHT OF FIRST REFUSAL. Except as provided in Section 2.4,
neither the Holding Company, the Operating Company, WRH/QIC nor any member of
WRH/QIC, shall enter into any transaction (or series of transactions) which
would constitute a Transfer of Control Transaction (as hereinafter defined),
unless at least twenty (20) days prior to entering into any such transaction (or
series of related transactions) (hereinafter a "Proposed Transaction"), PENAC is
notified in writing by the Holding Company, the Operating Company, WRH/QIC, or
the member of WRH/QIC, as the case may be (the "Relevant Seller(s)"), of any
such Proposed Transaction (the "First Refusal Notice") and is given the first
opportunity to enter into such Proposed Transaction with the Relevant Seller(s)
(the "Right of First Refusal") in the manner specified below. For purposes of
this Agreement, "Transfer of Control Transaction" shall mean (i) a sale or other
transfer of all or substantially all of the assets of Quinton Instrument Company
or any successor (the "Operating Company") or the Holding Company; (ii) any
merger, consolidation, refinancing, or recapitalization that changes the control
of the Operating Company or Holding Company; (iii) one or more transfers of
voting stock of the Holding Company which taken alone or together result in any
entity (including any "group" within the meaning of Section 13d-5 of the
Securities Exchange Act of 1934) other than WRH/QIC or any of the initial
members of WRH/QIC (other than Zymed), directly, indirectly, beneficially or
otherwise owning more than fifty percent (50%) of the outstanding voting stock
of the Holding Company; or (iv) one or more transfers of membership interests in
WRH/QIC (the "Units"), which taken alone or together result in any entity
(including any "group") other than WRH/QIC or any of the initial members of
WRH/QIC (other than Zymed), directly, indirectly, beneficially or otherwise
owning more than fifty percent (50%) of the Units of WRH/QIC.

                  2.1.1 FIRST REFUSAL NOTICE. The First Refusal Notice shall
specify the identity of the potential acquiror(s) (the "Acquiror"), the
structure of the Proposed Transaction, the interests that would be sold or
otherwise transferred, the price to be paid for such interests, the form of
consideration, the terms of payment and the time within which the Relevant
Seller(s) proposes to enter into any agreement to consummate such Proposed
Transaction, and all other material terms and conditions upon which the Relevant
Seller(s) proposes to enter into the Proposed Transaction (the "First Refusal
Terms"), subject to the customary conditions. The First Refusal Notice shall
include a representation from the party providing the notice that (i) the
Acquiror has entered into a non-binding term sheet or other non-binding
preliminary written document with the Relevant Seller(s) to enter into the
Proposed Transaction on the First Refusal Terms; (ii) to its knowledge, the
Acquiror is prepared to consummate the Proposed Transaction, subject to the
satisfaction of customary conditions; (iii) the Relevant Seller(s) has no reason
to believe that the Acquiror will not be able to obtain adequate financing; and
(iv) the Relevant Seller(s) have a good faith intention to enter into the
Proposed Transaction, subject to the satisfaction of customary conditions, on
the First Refusal Terms.

                  2.1.2 EXERCISE OF OPTION. The First Refusal Notice shall
constitute an irrevocable offer to PENAC to enter into such Proposed Transaction
with the Relevant Seller(s) on the First Refusal Terms or terms specified by
PENAC which include cash to the same extent as the First Refusal Terms and are
in other respects economically equivalent (i.e., PENAC may pay cash in lieu of
stock or other consideration) to the First Refusal Terms (the "PENAC Equivalent
Terms"). The Right of First Refusal shall be exercisable by notice from PENAC to
the Relevant Seller(s) within twenty (20) days of receipt by PENAC of the First
Refusal Notice (the "Option Period"). Such notice from PENAC shall specify
PENAC's Equivalent Terms, if any. If PENAC exercises the Right of First Refusal,
then the Relevant Seller(s) shall enter into such Proposed Transaction with
PENAC on the First Refusal Terms, or, if such terms are specified by PENAC, on
PENAC's Equivalent Terms and the Holding Company, the Operating Company,
WRH/QIC, and the members of WRH/QIC shall each use its best efforts and take
necessary actions to permit PENAC to complete the Proposed Transaction on the
First Refusal Terms. The closing of such Proposed Transaction shall take place
on the second business day after PENAC and all other relevant parties have
obtained or made all consents, approvals, orders, licenses, permits and
authorizations of, and registrations, declarations and filings with, any
governmental authority or any other person required to be obtained or made in
connection with the consummation of such Proposed Transaction, but not earlier
than twenty (20) days following the date PENAC gives notice exercising its Right
of First Refusal, nor more than one-hundred and twenty (120) days from the date
of that notice.

                  2.1.3 EXPIRATION OF OPTION PERIOD. If PENAC does not give the
Relevant Seller written notice of PENAC's desire to exercise this Right of First
Refusal within the Option Period, PENAC's Right of First Refusal shall terminate
and the Relevant Seller(s) may thereafter consummate the Proposed Transaction,
but only to the purchaser

                                       2
<PAGE>
identified in the First Refusal Terms and on terms and conditions not
substantially less favorable to the Relevant Seller than those contained in the
Term Sheet and provided that the sale must be consummated within one hundred and
twenty (120) days following the expiration of the Option Period. For purposes
hereof, a downward adjustment of more than five percent (5%) in the purchase
price to be paid at closing for the Offered Shares shall be deemed substantially
less favorable, but a downward adjustment of five percent (5%) or less shall not
be deemed substantially less favorable.

                  2.1.4 TERMINATION ON INITIAL PUBLIC OFFERING. PENAC's Right of
First Refusal shall automatically terminate in the event of any firm commitment,
underwritten initial public offering of common stock of the Holding Company or
the Operating Company (an "IPO") at a price per share of at least $2.00 (as
adjusted to reflect subsequent combinations, stock splits, stock dividends, or
other recapitalizations) and either (i) with aggregate proceeds of at least
$10,000,000, or (ii) in an IPO where PENAC sells (or has the right to but elects
not to sell) shares of the Holding Company or Operating Company which provide
aggregate proceeds to PENAC of at least $2,400,000.

         2.2 WRH/QIC RIGHT OF FIRST REFUSAL. Except as provided in Section 2.4,
if PENAC desires to sell, assign, transfer, or otherwise dispose of any of its
shares of the Holding Company, PENAC shall provide WRH/QIC with a First Refusal
Notice at least twenty (20) days prior to entering into such transaction and
WRH/QIC shall have a Right of First Refusal with respect to the proposed sale,
assignment, transfer or disposition, substantially as provided in Section 2.1.
For purposes of this Section, all references to "PENAC" in Sections 2.1.1
through 2.1.3 shall be read as "WRH/QIC", and all references to the "Relevant
Seller" shall be read as "PENAC."

                  2.2.1 TERMINATION ON INITIAL PUBLIC OFFERING. WRH/QIC's Right
of First Refusal shall automatically terminate upon termination of PENAC's Right
of First Refusal.

         2.3 CO-SALE. Except as provided in Section 2.4, if, after the
consummation of the transaction set forth in the First Refusal Notice, the
transferee (or any "Group") in such transaction will own more than fifty percent
(50%) of the outstanding voting stock of the Holding Company or more than fifty
percent (50%) of the Units of WRH/QIC, PENAC shall have the right, but not the
obligation, to sell its shares on the same terms and conditions as those
applicable to WRH/QIC, or the member of WRH/QIC, as specified in the First
Refusal Notice, including the same time of sale and the same per-share
consideration. If the Transfer of Control Transaction set forth in the First
Refusal Notice involves a sale of Units of WRH/QIC (rather than shares of stock
of the Holding Company), and if PENAC wishes to exercise its co-sale right, then
PENAC shall have the right to exchange with WRH/QIC that number of Shares for
that number of Units in WRH/QIC that would allow PENAC to achieve the same
economic result as described above in the context of a sale of Shares. As a
condition to making such exchange, and as promptly thereafter as practicable,
PENAC shall sell its Units on the same terms and conditions as applicable to the
member(s) of WRH/QIC that elected to sell their Units, including the same time
of sale and same per-Unit consideration, but not subject to any fees, costs, or
carrying interests which the members of WRH/QIC may pay under the Operating
Agreement; provided, however, that if the sale transaction is not consummated or
if PENAC does not sell its Units in such sale transaction, then PENAC's exchange
of Shares for Units shall be rescinded ab initio.

                  2.3.1 EXERCISE OF CO-SALE RIGHT. In order to exercise its
rights under this Section 2.3, PENAC shall give written notice thereof to
WRH/QIC and the Relevant Seller within twenty (20) business days from PENAC's
receipt of the First Refusal Notice, which notice shall either (i) specify the
number of shares that PENAC intends to sell, or (ii) if applicable, specify the
number of shares that PENAC intends to contribute to WRH/QIC in exchange for
Units to be sold in the transaction. No sales of shares or Units shall occur
until the expiration of such twenty (20) business day period. If the sum of the
number of shares or Units to be sold by WRH/QIC, PENAC and the members of
WRH/QIC pursuant to the exercise of these "tag-along" rights exceeds the number
of shares the purchaser is willing to buy, then WRH/QIC shall adjust the number
of shares or Units to be sold by WRH/QIC, PENAC and the members of WRH/QIC to
ensure that the ratio of the number of shares or Units proposed to be sold by
WRH/QIC, or the members of WRH/QIC, to the ratio of shares actually sold by
WRH/QIC, or the members of WRH/QIC, shall be equal to the ratio for PENAC.
WRH/QIC shall provide in its Operating Agreement that it has the right to adjust
the number of Units sold by its members to comply with this Section 2.3.

         2.4 PERMITTED TRANSFERS. Notwithstanding any of the provisions of this
Agreement, (i) any member of WRH/QIC may (a) transfer its Units in WRH/QIC to
other initial members of WRH/QIC, or to one or more trusts established by the
member for estate or succession planning purposes; or (b) pledge such Units as
collateral security to financial institutions or other non-operating companies
in accordance with Section 5 of this Agreement; provided,

                                       3
<PAGE>
however, that transfers can be made to Zymed only as long as Zymed holds
(whether directly, indirectly, beneficially, or otherwise) less than 19% of
WRH/QIC, and (ii) PENAC may transfer its shares in the Holding Company to KPNV
or to any one hundred percent (100%) (directly or indirectly) owned subsidiary
of KPNV.

         2.5 MANAGER OBLIGATION. The Manager covenants that it (and any
successor) shall not permit the members of WRH/QIC to transfer any interest in
WRH/QIC in any way which is inconsistent or in conflict with the provisions of
this Agreement or the Operating Agreement.

3.       INTERESTED PARTY TRANSACTIONS.

         3.1 INTERESTED PARTY. For the purposes of this Agreement, the phrase
"Interested Party" shall mean PENAC, Zymed, W.R. Hambrecht & Co., LLC ("WRH"),
WRH/QIC and their respective employees, affiliates, and investors.

         3.2 SIGNIFICANT TRANSACTIONS. Before the Holding Company or the
Operating Company may enter into any transaction with an Interested Party which
would under California corporate law require a shareholder vote, the transaction
shall have been approved by the Board of Directors at a meeting of the Board
held on notice to PENAC's nominee director and the Board shall have found that
the terms and conditions of such proposed transaction are not less favorable to
the Holding Company or the Operating Company, as the case may be, than could be
obtained on an arm's-length basis from unrelated third parties. If,
notwithstanding Board approval, PENAC believes that the terms of the transaction
are more favorable to the Interested Party than would have been obtained on an
arm's-length basis, PENAC shall notify the Board within five (5) business days
after the Board's approval of the transaction and PENAC may require the company
to submit the proposed transaction to an independent investment bank or
independent public accountants of recognized national standing (the "Neutral").
The Neutral shall review the proposed transaction and shall decide as soon as
possible, and in any event within thirty (30) days, whether the terms of the
proposed transaction are more favorable to the Interested Party than would have
been obtainable in an "arms' length" transaction. The proposed transaction shall
not proceed if the Neutral determines it is more favorable to the Interested
Party than would have been obtainable in an "arms' length" transaction unless
its terms are amended to satisfy the Neutral's determination of what provisions
were less than "arms' length."

         3.3 SALARY AND COMPENSATION ISSUES. Any salary, fee or compensation
matter (other than reimbursement of travel expenses of directors) which relates
to any employee, consultant or board member of the Holding Company or the
Operating Company who is an employee, consultant, director or Manager in WRH/QIC
or WRH (or in any entity which is controlled by WRH/QIC or WRH, or which
controls WRH/QIC or WRH), or an employee, consultant, or director of PENAC or
Zymed, shall require the unanimous consent of the Board of Directors; provided,
however, that the limitations in this Section 3.3 shall not apply to any
individual who is employed primarily by, or on a full time basis by the
Operating Company.

         3.4 AGREEMENTS WITH INTERESTED PARTIES. Except as provided in Section
3.2, before the Holding Company or Operating Company enters into any agreement
with an Interested Party, it shall have been approved by the Board of Directors
of the Holding Company at a meeting of the Board held on notice to PENAC's board
nominee and at which the interest of any director has been disclosed. No
director shall be disqualified from voting on the transaction by reason of such
interest. If, notwithstanding Board approval, PENAC believes that the terms of
the transaction are more favorable than would have been obtainable in an "arms'
length" transaction, PENAC shall notify the Board within five (5) days after the
Board's approval of the transaction and PENAC may require the company to submit
the proposed transaction to the Neutral. The Neutral shall review the proposed
transaction and shall decide as soon as possible, and in any event within thirty
(30) days, whether the terms of the proposed transaction are more favorable to
the Interested Party than would have been obtainable in an "arms' length"
transaction. If the Neutral decides that the terms are more favorable to the
Interested Party than would have been obtainable in an "arms' length"
transaction, then the proposed transaction shall not proceed unless its terms
are amended to satisfy the Neutral's determination of what provisions were less
than "arms' length."

4.       PLEDGES, HYPOTHECATIONS AND OTHER ENCUMBRANCES.

         4.1 SHARES OF THE HOLDING COMPANY. Neither Shareholder may pledge,
hypothecate, or otherwise

                                       4
<PAGE>
encumber its shares in the Holding Company as security for any debt without the
consent of the other Shareholder (which shall not be unreasonably withheld);
provided, however, that either Shareholder can so pledge, hypothecate, or
otherwise encumber its shares in connection with obtaining financing for the
Operating Company from a financial institution.

         4.2 INVESTORS IN WRH/QIC. WRH/QIC shall provide in its Operating
Agreement that no member of WRH/QIC may pledge, hypothecate, or otherwise
encumber its Units unless the secured creditor has agreed that, prior to selling
any or all of such Units in satisfaction of the debtor member's obligation, such
Units shall be offered to first to WRH/QIC, then to the other members of
WRH/QIC, and finally to HP to the extent that the Units are not purchased by
WRH/QIC or its members. If PENAC buys Units of WRH/QIC, those Units shall be
subject to all of the provision in the Operating Agreement of WRH/QIC, but not
subject to any fees, costs or carrying interest which the members of WRH/QIC may
pay under the Operating Agreement.

5.       TERMINATION OF AGREEMENT. This Agreement shall terminate on the
earliest of the written agreement of all parties and, except as necessary to
preserve any causes of action arising prior to such termination, such time as
only one Shareholder remains.

6.       LEGEND ON SHARES. Each Shareholder shall have placed on the
certificates representing its shares the following words:

         SALE, TRANSFER, HYPOTHECATION, ENCUMBRANCE, OR DISPOSITION OF THE
         SHARES REPRESENTED BY THIS CERTIFICATE IS RESTRICTED BY THE PROVISIONS
         OF A SHAREHOLDERS AGREEMENT AMONG THE SHAREHOLDERS DATED AUGUST 1,
         2001. ALL PROVISIONS OF THE SHAREHOLDERS AGREEMENT ARE INCORPORATED BY
         REFERENCE IN THIS CERTIFICATE. A COPY OF THE AGREEMENT MAY BE INSPECTED
         AT THE PRINCIPAL OFFICE OF QIC HOLDING CORP. AT 550 15TH STREET, SAN
         FRANCISCO, CALIFORNIA, 94103.

A copy of this Agreement shall be delivered to the secretary of the Holding
Company. Each Shareholder shall have the right to vote his or her shares and
receive the dividends paid on them until the shares are sold or transferred as
provided in this Agreement.

7.       RESTRICTIONS ON TRANSFEREES. Each transferee or any subsequent
transferee of shares in the Holding Company, or any interest in such shares,
shall hold the shares or interest in the shares subject to all provisions hereof
and shall make no transfers except as provided in this Agreement. Transfer of
the shares shall not be entered on the books of the Holding Company until an
amended copy of this Agreement has been executed by the prospective transferee.
Failure or refusal to sign such an amended copy of this Agreement shall not
relieve any transferee from any obligations under this Agreement. Any purported
transfer in violation of any provision of this Agreement shall be void ab initio
and shall not operate to transfer any right, title or interest to the purported
transferee.

8.       MISCELLANEOUS PROVISIONS.

         8.1. FURTHER ACTS. Each party to this Agreement agrees to perform any
further acts and execute and deliver any documents that may be reasonably
necessary to carry out the provisions of this Agreement.

         8.2. AMENDMENTS. The provisions of this Agreement may be waived,
altered, amended, modified, or repealed, in whole or in part, only on the
written consent of all parties to this Agreement.

         8.3. SUCCESSORS AND ASSIGNS. This Agreement shall be binding on and
enforceable by and against the parties to it and their respective heirs, legal
representatives, successors, and assigns.

         8.4. ENFORCEABILITY. All provisions of this Agreement are separate and
divisible, and if any part is held invalid, the remaining provisions shall
continue in full force and effect.

         8.5. NOTICES. All notices, requests, demands, and other communications
under this Agreement shall be in

                                       5
<PAGE>
writing and shall be deemed to have been duly given on the date of service if
served personally on the party to whom notice is to be given, or within three
business days after mailing, if mailed to the party to whom notice is to be
given, by first - class mail, registered or certified, postage prepaid, and
properly addressed to the party at the following addresses (or any other address
that a party may designate by written notice to the others):

                           a.       If to WRH/QIC, to:

                                    W.R. Hambrecht/QIC, LLC
                                    539 Bryant Street, Suite 100
                                    San Francisco, CA 94107
                                    ATTN:  J.D. Delafield

                           b.       If to PENAC, to:

                                    Medical Systems NA
                                    3000 Minuteman Road
                                    Andover, MA  01810
                                    ATTN:  S. Rusckowski

                                    With a copy to:

                                    Medical Systems NA
                                    3000 Minuteman Road, MS230
                                    Andover, MA  01810
                                    ATTN:  S. Freeman

                           c.       If to WRH/QIC Management, to:

                                    W.R. Hambrecht/QIC Management, LLC
                                    539 Bryant Street, Suite 100
                                    San Francisco, CA 94107
                                    ATTN:  J.D. Delafield

                           d.       If to the Holding Company, to:

                                    QIC Holding Corp.
                                    539 Bryant Street, Suite 100
                                    San Francisco, CA 94107
                                    ATTN:  J.D. Delafield

         8.6. CHOICE OF LAW. This Agreement shall be governed by, and construed
in accordance with, the internal laws of the State of California.

         8.7. COUNTERPARTS. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

         8.8. ENTIRE AGREEMENT. This Agreement constitutes the entire agreement
between the parties hereto pertaining to the subject matter hereof, and any and
all other written or oral agreements existing between the parties hereto are
expressly cancelled.

                                       6
<PAGE>
         IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first shown above.

                                 W.R. HAMBRECHT/QIC, LLC

                                 By: /s/ J.D. Delafield
                                    --------------------------------------------
                                 Name: J.D. Delafield
                                      ------------------------------------------
                                 Title:
                                       -----------------------------------------

                                 PHILIPS ELECTRONICS NORTH AMERICA CORPORATION

                                 By: /s/ Belinda W. Chew
                                    --------------------------------------------
                                 Name:   Belinda W. Chew
                                      ------------------------------------------
                                 Title:  Senior Vice President
                                       -----------------------------------------

                                 W.R. HAMBRECHT/QIC MANAGEMENT, LLC

                                 By: /s/ J.D. Delafield
                                    --------------------------------------------
                                 Name: J.D. Delafield
                                      ------------------------------------------
                                 Title: Manager
                                       -----------------------------------------<PAGE>
                                                                   EXHIBIT 10.14

                                QIC HOLDING CORP.

                           INVESTORS' RIGHTS AGREEMENT

          This Registration Rights Agreement (this "Agreement") is made and
entered into as of the 27th day of May, 1998, by and between QIC Holding Corp.,
a California corporation (the "Company"), on the one part, and W.R.
Hambrecht/QIC, LLC ("WRH/QIC"), a California limited liability corporation and
Hewlett-Packard Company ("HP"), a Delaware corporation (collectively the
"Purchasers"), on the other part.

                                    RECITALS

     A.   The Company has entered into a Subscription Agreement dated May 27,
1998 with WRH/QIC and HP (the "Subscription Agreement"), whereby the Company
agreed to sell 81 shares of its Class A Common Stock and 9,900,000 shares of its
Series A Preferred Stock to WRH/QIC, and 19 shares of its Class A Common Stock
and 2,330,000 shares of its Series A Preferred Stock to HP.

     B.   The obligations of the Company and the Purchasers under the
Subscription Agreements are conditioned, among other things, upon the execution
and delivery of this Agreement by the Company and the Purchasers.

          NOW, THEREFORE, in consideration of the mutual promises and covenants
hereinafter set forth, the parties hereto agree as follows:

          1.   Certain Definitions. As used in this Agreement, the following
terms shall have the meanings set forth below:

               a. "Agreement" shall mean this Registration Rights Agreement, as
it may be amended or supplemented from time to time.

               b. "Commission" shall mean the Securities and Exchange Commission
or any other federal agency at the time administering the Securities Act.

               c. "Preferred Stock" shall mean shares of Series A Preferred
Stock, in the Company.

               d. "Exchange Act" shall mean the Securities Exchange Act of 1934,
as amended, or any similar successor federal statute and the rules and
regulations thereunder, all as the same shall be in effect from time to time.

               e. "Holder" shall mean the Purchasers, to the extent the
Purchasers hold Registrable Securities, and any other holder of Registrable
Securities to whom the registration rights conferred by this Agreement have been
transferred in compliance with Sections 2 and 9 hereof.

<PAGE>

               f. "Indemnified Party" shall mean each party entitled to
indemnification under Section 6 herein.

               g. "Indemnifying Party" shall mean the party required to provide
indemnification pursuant to Section 6 herein.

               h. "Registrable Securities" shall mean: (1) shares of common
stock issued or issuable pursuant to conversion of the Preferred Stock; (2)
shares of Class A Common Stock; and (3) any common stock issued or issuable as a
dividend or other distribution with respect to or in exchange for or in
replacement of the shares referenced in (1) above; provided, however, that
Registrable Securities shall not include any shares of common stock which have
previously been registered or which have been sold in a private transaction in
which the transferors rights under this Agreement are not assigned.

               i. The terms "register," "registered" and "registration" shall
refer to a registration effected by preparing and filing a registration
statement in compliance with the Securities Act and applicable rules and
regulations thereunder, and the declaration or ordering of the effectiveness of
such registration statement.

               j. "Registration Expenses" shall mean all expenses incurred in
effecting any registration pursuant to this Agreement, including, without
limitation, all registration, qualification, and filing fees, printing expenses,
escrow fees, fees and disbursements of counsel for the Company, blue sky fees
and expenses, and expenses of any regular or special audits incident to or
required by any such registration, but shall not include Selling Expenses, fees
and disbursements of counsel for the Holders; provided further that Registration
Expenses shall not include the compensation of regular employees of the Company,
which shall be paid in any event by the Company.

               k. "Restricted Securities" shall mean any Registrable Securities
required to bear the legend set forth in Section 2 hereof.

               l. "Rule 144" shall mean Rule 144 as promulgated by the
Commission under the Securities Act, as such Rule may be amended from time to
time, or any similar successor rule that may be promulgated by the Commission.

               m. "Rule 145" shall mean Rule 145 as promulgated by the
Commission under the Securities Act, as such Rule may be amended from time to
time, or any similar successor rule that may be promulgated by the Commission.

               n. "Rule 415" shall mean Rule 415 as promulgated by the
Commission under the Securities Act, as such Rule may be amended from time to
time, or any similar successor rule that may be promulgated by the Commission.

                                       2
<PAGE>

               o. "Securities Act" shall mean the Securities Act of 1933, as
amended, or any similar successor federal statute and the rules and regulations
thereunder, all as the same shall be in effect from time to time.

               p. "Selling Expenses" shall mean all underwriting discounts,
selling commissions and stock transfer taxes applicable to the sale of
Registrable Securities and fees and disbursements of counsel for any Holders
(other than the fees and disbursements of counsel included in Registration
Expenses).

          2.   Restrictions on Transfer.

               a. Each Holder agrees not to make any disposition of all or any
portion of the Registrable Securities unless and until the transferee has agreed
in writing for the benefit of the Company to be bound by this Section 2,
provided and to the extent such Section is then applicable, and:

               b. There is then in effect a registration statement under the
Securities Act covering such proposed disposition and such disposition is made
in accordance with such registration statement; or

               c. The Holder has (i) notified the Company of the proposed
disposition and has furnished the Company with a detailed statement of the
circumstances surrounding the proposed disposition, and (ii) if reasonably
requested by the Company, has furnished the Company with an opinion of counsel,
reasonably satisfactory to the Company, that such disposition will not require
registration of such shares under the Securities Act. It is agreed that the
Company will not require opinions of counsel for transactions made pursuant to
Rule 144 except in unusual circumstances

               d. Notwithstanding the provisions of paragraphs (b) and (c)
above, no such registration statement or opinion of counsel shall be necessary
for a transfer by a Holder which is (i) a partnership to its partners or retired
partners in accordance with partnership interests, (ii) a corporation to its
shareholders in accordance with their interest in the corporation, (iii) a
limited liability company to its members or former members in accordance with
their interest in the limited liability company, (iv) to the Holder's family
member or trust for the benefit of an individual Holder, provided the transferee
will be subject to the terms of this Section 2 to the same extent as if such
transferee were an original Holder hereunder, or (v) to a wholly-owned
subsidiary of HP.

               e. Each certificate representing Registrable Securities shall
(unless otherwise permitted by the provisions of this Agreement) be stamped or
otherwise imprinted with a legend substantially similar to the following (in
addition to any legend required under applicable state securities laws):

        THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
        SECURITIES ACT OF 1933, AS AMENDED, AND MAY NOT BE SOLD OR
        TRANSFERRED, ASSIGNED, PLEDGED OR

                                       3
<PAGE>

        HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SUCH ACT OR UNLESS
        THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL OR OTHER EVIDENCE,
        SATISFACTORY TO THE COMPANY AND ITS COUNSEL, THAT SUCH
        REGISTRATION IS NOT REQUIRED.

               f. The Company shall be obligated to reissue promptly unlegended
certificates at the request of any holder thereof if the holder shall have
obtained an opinion of counsel at such Holder's expense (which counsel may be
counsel to the Company) reasonably acceptable to the Company to the effect that
the securities proposed to be disposed of may lawfully be so disposed of without
registration, qualification or legend.

               g. Any legend endorsed on an instrument pursuant to applicable
state securities laws and the stop-transfer instructions with respect to such
securities shall be removed upon receipt by the Company of an order of the
appropriate blue sky authority authorizing such removal.

          3.   Company Registration.

               a. If the Company shall determine to register any of its
securities, other than its initial public offering, or a registration relating
solely to employee benefit plans, or a registration relating to a corporate
reorganization or other transactions under Rule 145, or a registration on any
registration form that does not permit secondary sales, the Company will:

                    (1) promptly give to each Holder written notice thereof; and

                    (2) use its best efforts to include in such registration
(and any related qualification under blue sky laws or other compliance), except
as set forth in Section 3(b) below, and in any underwriting involved therein,
all the Registrable Securities specified in a written request or requests, made
by any Holder and received by the Company within ten (10) days after the written
notice from the Company described in clause (1) above is mailed or delivered by
the Company. Such written request may specify all or a part of a Holder's
Registrable Securities.

               b. If the registration of which the Company gives notice is for a
registered public offering involving an underwriting, the Company shall so
advise the Holders as a part of the written notice given pursuant to Section
3(a)(1). In such event, the right of any Holder to registration pursuant to this
Section 3 shall be conditioned upon such Holder's participation in such
underwriting and the inclusion of such Holder's Registrable Securities in the
underwriting to the extent provided herein. All Holders proposing to distribute
their securities through such underwriting shall (together with the Company and
the other holders of securities of the Company with registration rights to
participate therein distributing their securities through such underwriting)
enter into an underwriting agreement in customary form with the representative
of the underwriter or underwriters selected by the Company.

                    (1) Notwithstanding any other provision of this Section 3,
if the representative of the underwriters advises the Company in writing that
marketing factors

                                       4
<PAGE>

require a limitation on the number of shares to be underwritten, the
representative may (subject to the limitations set forth below) exclude all
Registrable Securities from, or limit the number of Registrable Securities to be
included in, the registration and underwriting. The Company shall so advise all
holders of securities requesting registration, and the number of shares of
securities that are entitled to be included in the registration and underwriting
shall be allocated first to the Company for securities being sold for its own
account and thereafter as set forth in Section 11. If any person does not agree
to the terms of any such underwriting, he shall be excluded therefrom by written
notice from the Company or the underwriter. Any Registrable Securities or other
securities excluded or withdrawn from such underwriting shall be withdrawn from
such registration.

                    (2) If shares are so withdrawn from the registration or if
the number of shares of Registrable Securities to be included in such
registration was previously reduced as a result of marketing factors, the
Company shall then offer to all persons who have retained the right to include
securities in the registration the right to include additional securities in the
registration in an aggregate amount equal to the number of shares so withdrawn,
with such shares to be allocated among the persons requesting additional
inclusion in accordance with Section 11 hereof.

          4. Expenses of Registration. All Registration Expenses incurred in
connection with any registration, qualification or compliance pursuant to
Section 3 hereof shall be borne by the Company. All Selling Expenses relating to
securities so registered shall be borne by the holders of such securities pro
rata on the basis of the number of shares of securities so registered on their
behalf, as shall any other expenses in connection with the registration required
to be borne by the Holders of such securities.

          5.  Registration Procedures. In the case of each registration effected
by the Company pursuant to this Agreement, the Company will keep each Holder
advised in writing as to the initiation of each registration and as to the
completion thereof. At its expense, the Company will use its best efforts to:

               a. Keep such registration effective for a period of one hundred
twenty (120) days or until the Holder or Holders have completed the distribution
described in the registration statement relating thereto, whichever first
occurs; provided, however, that (i) such 120-day period shall be extended for a
period of time equal to the period the Holder refrains from selling any
securities included in such registration at the request of an underwriter of
common stock (or other securities) of the Company; and (ii) in the case of any
registration of Registrable Securities on Form S-3 which are intended to be
offered in a continuous or delayed basis, such 120-day period shall be extended,
if necessary, to keep the registration statements effective until all such
Registrable Securities are sold, provided that if Rule 415, or any successor
rule under the Securities Act, permits an offering on a continuous or delayed
basis and provided further that applicable rules under the Securities Act
governing the obligation to file a post- effective amendment permit, in lieu of
filing a post-effective amendment that (I) includes any prospectus required by
Section 10(a)(3) of the Securities Act; or (II) reflects facts or events
representing a material or fundamental change in the information set forth in
the registration statement, the incorporation by reference to information
required to be included in (I) and (II)

                                       5
<PAGE>

above to be contained in periodic reports filed pursuant to Section 13 or 15(d)
of the Exchange Act in the registration statement;

               b. Prepare and file with the Commission such amendments and
supplements to such registration statement and the prospectus used in connection
with such registration statement as may be necessary to comply with the
provisions of the Securities Act with respect to the disposition of all
securities covered by such registration statement;

               c. Furnish such number of prospectuses and other documents
incident thereto, including any amendment of or supplement to the prospectus, as
a Holder from time to time may reasonably request;

               d. Notify each seller of Registrable Securities covered by such
registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening of any event
as a result of which the prospectus included in such registration statement, as
then in effect, includes an untrue statement of a material fact or omits to
state a material fact required to be stated therein or necessary to make the
statements therein not misleading or incomplete in the light of the
circumstances then existing, and at the request of any such seller, prepare and
furnish to such seller a reasonable number of copies of a supplement to or an
amendment of such prospectus as may be necessary so that, as thereafter
delivered to the purchasers of such shares, such prospectus shall not include an
untrue statement of a material fact or omit to state a material fact required to
be stated therein or necessary to make the statements therein not misleading or
incomplete in the light of the circumstances then existing;

               e. In connection with any underwritten offering pursuant to a
registration statement filed pursuant to this Agreement, the Company will enter
into an underwriting agreement in form reasonably necessary to effect the offer
and sale of stock, provided such underwriting agreement contains customary
underwriting provisions, and provided further that if the underwriter so
requests the underwriting agreement will contain customary contribution
provisions;

               f. Cause all such Registrable Securities registered pursuant
hereunder to be listed on each securities exchange on which similar securities
issued by the Company are then listed;

               g. Provide a transfer agent and registrar for all Registrable
Securities registered pursuant hereunder and a CUSIP number for all such
Registrable Securities, in each case not later than the effective date of such
registration; and

               h. Furnish, at the request of any Holder requesting registration
pursuant to Section 3 hereof, on the date that such Registrable Securities are
delivered to the underwriters for sale in connection with a registration
pursuant to Section 3 hereof, if such securities are being sold through
underwriters, or, if such securities are not being sold through underwriters, on
the date that the registration statement with respect to such securities becomes
effective, (i) an opinion, dated such date, of the counsel representing the
Company for the

                                       6
<PAGE>

purposes of such registration, in form and substance as is customarily given to
underwriters in an underwritten public offering, addressed to the underwriters,
if any, and to the Holders requesting registration of Registrable Securities and
(ii) a letter dated such date, from the independent certified public accountants
of the Company, in form and substances as is customarily given by independent
certified public accountants to underwriters in an underwritten public offering,
addressed to the underwriters, if any, and to the Holders requesting
registration of Registrable Securities.

          6.   Indemnification.

               a. The Company will indemnify each Holder, each of its officers,
directors and partners, legal counsel, and accountants and each person
controlling such Holder within the meaning of Section 15 of the Securities Act,
with respect to which registration, qualification, or compliance has been
effected pursuant to this Agreement, and each underwriter, if any, and each
person who controls within the meaning of Section 15 of the Securities Act any
underwriter, against all expenses, claims, losses, damages, and liabilities (or
actions, proceedings, or settlements in respect thereof) arising out of or based
on any untrue statement (or alleged untrue statement) of a material fact
contained in any prospectus, offering circular, or other document (including any
related registration statement, notification, or the like) incident to any such
registration, qualification, or compliance, or based on any omission (or alleged
omission) to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, or any violation by the
Company of the Securities Act or any rule or regulation thereunder applicable to
the Company and relating to action or inaction required of the Company in
connection with any such registration, qualification, or compliance, and will
reimburse each such Holder, each of its officers, directors, partners, legal
counsel, and accountants and each person controlling such Holder, each such
underwriter, and each person who controls any such underwriter, for any legal
and any other expenses reasonably incurred in connection with investigating and
defending or settling any claim, loss, damage, liability, or action, provided
that the Company will not be liable in any such case to the extent that any such
claim, loss, damage, liability, or expense arises out of or is based on any
untrue statement or omission based upon written information furnished to the
Company by such Holder or underwriter and stated to be specifically for use
therein. It is agreed that the indemnity agreement contained in this Section
6(a) shall not apply to amounts paid in settlement of any such loss, claim,
damage, liability, or action if such settlement is effected without the consent
of the Company (which consent has not been unreasonably withheld).

               b. Holder will, if Registrable Securities held by such Holder are
included in the securities as to which such registration, qualification, or
compliance is being effected, indemnify the Company, each of its directors,
officers, partners, legal counsel, and accountants and each underwriter, if any,
of the Company's securities covered by such a registration statement, each
person who controls the Company or such underwriter within the meaning of
Section 15 of the Securities Act, each other such Holder, and each of its
officers, directors, and partners, and each person controlling such Holder,
against all claims, losses, damages and liabilities (or actions in respect
thereof) arising out of or based on any untrue statement (or alleged untrue
statement) of a material fact contained in any such registration statement,
prospectus, offering circular, or other document, or any omission (or alleged

                                       7
<PAGE>

omission) to state therein a material fact required to be stated therein or
necessary to make the statements therein not misleading, and will reimburse the
Company and such Holders, directors, officers, partners, legal counsel, and
accountants, persons, underwriters, or control persons for any legal or any
other expenses reasonably incurred in connection with investigating or defending
any such claim, loss, damage, liability, or action, in each case to the extent,
but only to the extent, that such untrue statement (or alleged untrue statement)
or omission (or alleged omission) is made in such registration statement,
prospectus, offering circular, or other document in reliance upon and in
conformity with written information furnished to the Company by such Holder and
stated to be specifically for use therein; provided, however, that the
obligations of such Holder hereunder shall not apply to amounts paid in
settlement of any such claims, losses, damages, or liabilities (or actions in
respect thereof) if such settlement is effected without the consent of such
Holder (which consent shall not be unreasonably withheld); and provided that in
no event shall any indemnity under this Section 6 exceed the gross proceeds from
the offering received by such Holder.

               c. The "Indemnified Party" shall give notice to the Indemnifying
Party promptly after such Indemnified Party has actual knowledge of any claim as
to which indemnity may be sought, and shall permit the Indemnifying Party to
assume the defense of such claim or any litigation resulting therefrom, provided
that counsel for the Indemnifying Party, who shall conduct the defense of such
claim or any litigation resulting therefrom, shall be approved by the
Indemnified Party (whose approval shall not unreasonably be withheld), and the
Indemnified Party may participate in such defense at such party's expense, and
provided further that the failure of any Indemnified Party to give notice as
provided herein shall not relieve the Indemnifying Party of its obligations
under this Section 6, to the extent such failure is not prejudicial. No
Indemnifying Party, in the defense of any such claim or litigation, shall,
except with the consent of each Indemnified Party, consent to entry of any
judgment or enter into any settlement that does not include as an unconditional
term thereof the giving by the claimant or plaintiff to such Indemnified Party
of a release from all liability in respect to such claim or litigation. Each
Indemnified Party shall furnish such information regarding itself or the claim
in question as an Indemnifying Party may reasonably request in writing and as
shall be reasonably required in connection with defense of such claim and
litigation resulting therefrom.

               d. If the indemnification provided for in this Section 6 is held
by a court of competent jurisdiction to be unavailable to an Indemnified Party
with respect to any loss, liability, claim, damage, or expense referred to
therein, then the Indemnifying Party, in lieu of indemnifying such Indemnified
Party hereunder, shall contribute to the amount paid or payable by such
Indemnified Party as a result of such loss, liability, claim, damage, or expense
in such proportion as is appropriate to reflect the relative fault of the
Indemnifying Party on the one hand and of the Indemnified Party on the other in
connection with the statements or omissions that resulted in such loss,
liability, claim, damage, or expense as well as any other relevant equitable
considerations. The relative fault of the Indemnifying Party and of the
Indemnified Party shall be determined by reference to, among other things,
whether the untrue or alleged untrue statement of a material fact or the
omission to state a material fact relates to information supplied by the
Indemnifying Party or by the Indemnified Party and the parties' relative intent,
knowledge, access to information, and opportunity to correct or prevent such
statement or omission.

                                       8
<PAGE>

               e. Notwithstanding the foregoing, to the extent that the
provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are
in conflict with the foregoing provisions, the provisions in the underwriting
agreement shall control.

          7. Information by Holder. Each Holder shall furnish to the Company
such information regarding such Holder and the distribution proposed by such
Holder as the Company may reasonably request in writing and as shall be
reasonably required in connection with any registration, qualification, or
compliance referred to in this Agreement.

          8. Rule 144 Reporting. With a view to making available the benefits of
certain rules and regulations of the Commission that may permit the sale of the
Restricted Securities to the public without registration, the Company agrees to
use its best efforts to:

               a. Make and keep public information regarding the Company
available as those terms are understood and defined in Rule 144 under the
Securities Act, at all times commencing ninety (90) days after the effective
date of the first registration statement filed by the Company for the offering
of its securities to the general public;

               b. File with the Commission in a timely manner all reports and
other documents required of the Company under the Securities Act and the
Exchange Act;

               c. So long as a Holder owns any Restricted Securities, furnish to
the Holder forthwith upon written request: (i) a written statement by the
Company as to its compliance with the reporting requirements of Rule 144 (within
ninety (90) days after the Company's initial public offering) and of the
Securities Act and the Exchange Act (after it becomes subject to reporting
requirements), (ii) a copy of the most recent annual or quarterly report of the
Company, and (iii) such other reports and documents so filed as a Holder may
reasonably request in availing itself of any rule or regulation of the
Commission allowing a Holder to sell any such securities without registration.

          9. Transfer or Assignment of Registration Rights. The rights granted
to Holder under Section 3 to cause the Company to register securities under this
Agreement may be transferred or assigned by a Holder only to a transferee or
assignee of not less than 1,200,000 shares of Registrable Securities (as
presently constituted and calculated based upon the then effective conversion
price for the Preferred Stock, and subject to subsequent adjustments for stock
splits, stock dividends, reverse stock splits, and the like), provided that the
Company is given written notice at the time of or within a reasonable time after
said transfer or assignment, stating the name and address of the transferee or
assignee and identifying the securities with respect to which such registration
rights are being transferred or assigned, and, provided further, that the
transferee or assignee of such rights assumes in writing the obligations of such
Holder under this Agreement.

          10. "Market Stand-Off" Agreement. If requested by an underwriter of
common stock (or other securities) of the Company, a Holder shall not sell or
otherwise transfer

                                       9
<PAGE>

or dispose of any common stock (or other securities) of the Company held by such
Holder (other than those included in the registration) during the one hundred
eighty (180) day period following the effective date of a registration statement
of the Company filed under the Securities Act. The obligations described in this
Section 10 shall not apply to a registration relating solely to employee benefit
plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the
future.

          11. Allocation of Registration Opportunities. In any circumstance in
which all of the Registrable Securities requested to be included in a
registration on behalf of the Holders cannot be so included as a result of
limitations of the aggregate number of shares of Registrable Securities that may
be so included, the number of shares of Registrable Securities that may be so
included shall be allocated among the Holders requesting inclusion of shares pro
rata on the basis of the number of shares of Registrable Securities that would
be held by such Holders, assuming conversion; provided, however, that such
allocation shall not operate to reduce the aggregate number of Registrable
Securities to be included in such registration. If any Holder does not request
inclusion of the maximum number of shares of Registrable Securities allocated to
him pursuant to the above-described procedure, the remaining portion of his
allocation shall be reallocated among those requesting Holders whose allocations
did not satisfy their requests pro rata on the basis of the number of shares of
Registrable Securities which would be held by such Holders, assuming conversion,
and this procedure shall be repeated until all of the shares of Registrable
Securities which may be included in the registration on behalf of the Holders
have been so allocated.

          12. Delay of Registration. No Holder shall have any right to take any
action to restrain, enjoin, or otherwise delay any registration as the result of
any controversy that might arise with respect to the interpretation or
implementation of this Agreement.

          13. Termination of Registration Rights. The right of the Holder to
request inclusion in any registration pursuant to Section 3 shall terminate on
the earlier of (i) five years from the date hereof and (ii) as of such date that
all of the shares of Registrable Securities held by such Holder may immediately
be sold under Rule 144 during any 90-day period.

          14.  Basic Financial Information. The Company will furnish the
following reports to each Holder:

               a. As soon as practicable after the end of each fiscal year of
the Company, in any event within ninety (90) days thereafter, a consolidated
balance sheet of the Company and its subsidiaries, if any, as of the end of such
fiscal year, and consolidated statements of income and cash flows of the Company
and its subsidiaries, if any, for such year, prepared in accordance with
generally accepted accounting principles consistently applied and setting forth
in each case in comparative form the figures from the previous fiscal year, all
in reasonable detail and certified by independent certified public accountants
selected by the Company.

               b. As soon as practicable after the end of the first, second and
third quarterly accounting periods in each fiscal year of the Company, and in
any event within forty-

                                       10
<PAGE>

five (45) days thereafter, a consolidated balance sheet of the Company and its
subsidiaries, if any, as of the end of each such quarterly period, and
consolidated statements of income and cash flows of the Company and its
subsidiaries, if any, for such period and for the current fiscal year to date,
prepared in accordance with generally accepted accounting principles
consistently applied and setting forth in each case in comparative form the
figures for the corresponding periods of the previous fiscal year, subject to
changes resulting from normal year-end audit adjustments, all in reasonable
detail and certified by the principal financial or accounting officer of the
Company, except that such financial statements need not contain the notes
required by generally accepted accounting principles.

               c. At the request of a Holder, copies of annual operating budgets
for the upcoming fiscal year that have been provided to Silicon Valley Bank
under the terms of its loan and security agreement.

               d. From the date the Company becomes subject to the reporting
requirements of the Exchange Act (which shall include any successor federal
statute), and in lieu of the financial information required pursuant to Sections
14(a) and 14(b), the Company shall file copies of its annual reports on Form
10-K and its quarterly reports on Form 10-Q, respectively.

          15.  Inspection Rights.

               a. The Company will permit any holder, so long as they own at
least 1,200,000 shares of the Series A Preferred Stock, or such number of shares
of Class A Common Stock issued upon conversion of 1,200,000 shares of the Series
A Preferred Stock, or any combination thereof (as presently constituted and
subject to subsequent adjustment for stock splits, stock dividends, reverse
stock splits and the like) (a "Significant Holder") (or a representative of any
Significant Holder) to visit and inspect any of the properties of the Company,
including its books of account and other records (and make copies thereof and
take extracts therefrom), and to discuss its affairs, finances and accounts with
the Company's officers and its independent public accountants, all at such
reasonable times and as often as any such person may reasonably request.

               b. Notwithstanding any of the provisions in Section 15, no Holder
or Significant Holder shall have access to any trade secrets or classified
information of the Company by reason of this agreement. Each Significant Holder
hereby agrees to hold in confidence and trust and not to misuse or disclose
confidential information provided pursuant to this Section 15. The Company shall
not be required to comply with this Section 15 in respect of any Holder of
Significant Holder whom the Company reasonably determines to be a competitor or
any officer, employee, director or greater than ten percent (10%) stockholder of
a competitor.

          16. Right of First Refusal. The Company hereby grants to each
Holder who owns any shares of Series A Preferred Stock or any shares of Common
Stock issued upon conversion of Series A Preferred Stock the right of first
refusal to purchase a pro rata share of New Securities (as defined in this
Section 16) which the Company may, from time to time, propose to sell and issue.
A Holder's pro rata share, for purposes of this right of first refusal, is

                                       11
<PAGE>

the ratio of the number of shares of Common Stock owned by such Holder
immediately prior to the issuance of New Securities, assuming full conversion of
the Class A Preferred Stock and exercise of all outstanding rights, options and
warrants to acquire Common Stock of the Company. Each Holder shall have a right
of over-allotment such that if any Holder fails to exercise its right hereunder
to purchase its pro rata share of New Securities, the other Holders may purchase
the non-purchasing Holder's portion on a pro rata basis within ten (10) days
from the date such non-purchasing Holder fails to exercise its right hereunder
to purchase its pro rata share of New Securities. This right of first refusal
shall be subject to the following provisions:

               a. "New Securities" shall mean any capital stock (including
Common Stock and/or Preferred Stock) of the Company whether now authorized or
not, and rights, options and warrants to purchase such capital stock, and
securities of any type whatsoever that are, or may become, convertible into
capital stock; provided that the term "New Securities" does not include (i)
securities issued upon conversion of the Series A Preferred Stock; (ii)
securities issued pursuant to the bona fide acquisition of another business
entity or business segment of any such entity by the Company by merger, purchase
of substantially all the assets or other reorganization whereby the Company will
own more than fifty percent (50%) of the voting power of such business entity or
business segment of any such entity; (iii) any borrowings, direct or indirect,
from entities other than institutional lenders by the Company, whether or not
presently authorized, including any type of loan or payment evidenced by any
type of debt instrument, provided such borrowings do not have any equity
features including warrants, options or other rights to purchase capital stock
and are not convertible into capital stock of the Company; (iv) securities
issued or issuable upon exercise of options issued to institutional lenders in
connection with financing commitments to the Company; (v) securities issued to
employees, consultants, officers or directors of the Company pursuant to any
stock option; stock purchase or stock bonus plan, agreement, or arrangement
approved by a majority of the Board of Directors; (vi) securities issued to
vendors or customers or to other persons in similar situations with the Company
if such issuance is approved by the Board of Directors; (vii) securities issued
in connection with obtaining lease financing, whether issued to a lessor,
guarantor or other person; (viii) securities issued in a public offering
pursuant to a registration under the Securities Act with an aggregate offering
price to the public of at least $10,000,000; (ix) securities issued in
connection with any stock split, stock dividend or recapitalization of the
Company; (x) securities issued in connection with corporate partnering
transactions on terms approved by a majority of the Board of Directors, provided
such issuances are for other than primarily equity financing purposes; and (xi)
any right, option or warrant to acquire any security convertible into the
securities excluded from the definition of New Securities pursuant to
subsections (i) through (x) above.

               b. In the event the company proposes to undertake an issuance of
New Securities, it shall give each Holder written notice of its intention,
describing the type of New Securities, and their price and the general terms
upon which the Company proposes to issue the same. Each Holder shall have twenty
(20) days after such notice is mailed or delivered to agree to purchase such
Holder's pro rata share of such New Securities for the price and upon the terms
specified in the notice by giving written notice to the Company and stating
therein the quantity of New Securities to be purchased.

                                       12
<PAGE>

               c. In the event the Holders fail to exercise fully the right of
first refusal within said twenty (20) day period and after the expiration of the
10-day period for the exercise of the over-allotment provision of this Section
16, the Company shall have one hundred twenty (120) days thereafter to sell or
enter into an agreement (pursuant to which the sale of New Securities covered
thereby shall be closed, if at all, within one hundred twenty (120) days from
the date of said agreement) to sell the New Securities respecting which the
Holders' right of first refusal option set forth in this Section 16 was not
exercised, at a price and upon terms no more favorable to the purchasers thereof
than specified in the Company's notice to Holders pursuant to Section 16(b). In
the event the Company has not sold within said 120-day period, or entered into
an agreement to sell the New Securities in accordance with the foregoing within
one hundred twenty (120) days from the date of said agreement, the Company shall
not thereafter issue or sell any New Securities, without first again offering
such securities to the Holders in the manner specified in Section 16(b) above.

               d. The right of first refusal granted under this Agreement shall
expire upon, and shall not be applicable to, the first sale of Common Stock of
the Company to the public effected pursuant to a registration statement filed
with, and declared effective by, the Securities and Exchange Commission (the
"Commission") under the Securities Act, with proceeds of more than $10,000,000
and shall in any event expire on June 1, 2005.

               e. The right of first refusal set forth in this Section 16 may
not be assigned or transferred, except that (i) such right is assignable by each
Holder to any wholly-owned subsidiary or parent of, or to any corporation or
entity that is, within the meaning of the Securities Act, controlling,
controlled by or under common control with, any such Holder, and (ii) such right
is assignable between and among any of the Holders.

          17. Termination. The covenants set forth in Sections 14 and 15
shall terminate and be of no further force and effect after the closings of the
Company's first firm commitment underwritten public offering registered under
the Securities Act in which all shares of Series A Preferred Stock are converted
to Common Stock is consummated or where the Company becomes subject to the
periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act,
whichever event shall first occur.

          18. Governing Law.  This Agreement shall be governed in all respects
by the internal laws of the State of California without regard to conflict of
laws provisions.

          19.  Successors and Assigns. Except as otherwise expressly provided
herein, the provisions hereof shall inure to the benefit of, and be binding
upon, the successors, assigns, heirs, executors and administrators of the
parties hereto.

          20. Entire Agreement; Amendment; Waiver. This Agreement constitutes
the full and entire understanding and agreement between the parties with regard
to the subject hereof No party shall be liable or bound to any other party by
any warranties, representations or covenants except as specifically herein set
forth. This Agreement supersedes any prior written or oral agreement or
understanding with respect to the subject matter hereof. Except as expressly
provided herein, neither this Agreement nor any term hereof may be amended,
waived,

                                       13
<PAGE>

discharged or terminated other than by a written instrument signed by the party
against whom enforcement of any such amendment, waiver, discharge or termination
is sought.

          21. Notices. All notices, requests and other communications to any
party hereunder shall be in writing and addressed to the respective parties
at the following addresses (or at such address for a party as shall be specified
in a notice given in accordance with this Section 17):

               a. If to WRH/QIC, to:

                  W.R. Hambrecht/QIC, LLC
                  550 15th Street
                  San Francisco, CA 94103
                  ATTN:  J.D. Delafield

               b. If to HP, to:

                  Hewlett-Packard Company
                  3000 Hanover Street
                  Palo Alto, CA 94304
                  Mailstop 20 BT
                  ATTN: Director, Corporate Development

                  With a copy to:

                  Hewlett-Packard Company
                  3000 Hanover Street
                  Palo Alto, CA 94304
                  Mailstop 20 BQ
                  ATTN: General Counsel

               c. If to the Company, to:

                  QIC Holding Corp.
                  550 15th Street
                  San Francisco, CA 94103
                  ATTN: J. D. Delafield

          All notices under this Section 21 shall be deemed to have been given
upon receipt if delivered in person and shall be deemed to have been given (a)
two (2) business days after transmission of a facsimile, telegram, telex, or (b)
four (4) business days after deposit in United States registered or certified
mail (postage prepaid, return receipt requested) or (c) two (2) business days
after delivery to a reputable overnight courier.

          22. Delays or Omissions. Except as expressly provided herein, no delay
or omission to exercise any right, power or remedy accruing to any party, upon
any breach or

                                       14
<PAGE>

default of another party under this Agreement, shall impair anysuch right, power
or remedy of such party nor shall it be construed to be a waiver of any such
breach of default, or an acquiescence therein, or of or in any similar breach or
default thereafter occurring; nor shall any waiver of any single breach or
default be deemed a waiver of any other breach or default theretofore or
thereafter occurring. Any waiver, permit, consent or approval of any kind or
character on the part of any party of any breach or default under this
Agreement, or any waiver on the part of any party of any provisions or
conditions of this Agreement, must be in writing and shall be effective only to
the extent specifically set forth in such writing. All remedies, either under
this Agreement or by law or otherwise afforded, to any party, shall be
cumulative and not alternative.

          23. Counterparts. This Agreement may be executed in any number of
counterparts, each of which shall be an original, and all of which together
shall constitute one instrument.

          24. Severability. In the event that any provision of this Agreement
becomes or is declared by a court of competent jurisdiction to be illegal,
unenforceable or void, this Agreement shall continue in full force and effect
without said provisions, which shall be replaced with an enforceable provision
closest in intent and economic effect as the severed provision; provided that no
such severability shall be effective if it materially changes the economic
benefit of this Agreement to any party.

          25. Titles and Subtitles. The titles and subtitles used in this
Agreement are for convenience only and are not to be considered in construing or
interpreting this Agreement.

     IN WITNESS WHEREOF, the parties hereto have executed this Registration
Rights Agreement effective as of the day and year first above written.

                                        QIC HOLDING CORP.

                                        By: /s/ J.D. Delafield
                                            ------------------------------------
                                        Name: J.D. Delafield
                                              ----------------------------------
                                        Title: President
                                               ---------------------------------

                                        W.R. HAMBRECHT/QIC, LLC
                                        By: W.R. Hambrecht/QIC
                                            Management, LLC
                                            Manager

                                        By: /s/ J.D. Delafield
                                            ------------------------------------
                                        Name: J.D. Delafield
                                              ----------------------------------
                                        Title: Manager
                                               ---------------------------------

                                        HEWLETT-PACKARD COMPANY

                                        By: /s/ Stephen H. Rusckowski
                                            ------------------------------------
                                        Name: General Manager
                                              ----------------------------------
                                        Title: Cardiology Products Division
                                               ---------------------------------
                                               Stephen H. Rusckowski

                                       15

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00034-of-00352.parquet"}]]